Podcast: topical rapamycin for aging skin and the path to FDA approval
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedIn this podcast description, host Matt Kaeberlein talks with Chris Sell and Christina Chung of Hayflick Therapeutics about rapamycin, mTOR and cellular senescence in skin, and about their move from basic science to a controlled human study of topical rapamycin. [1]
The description says early experiments showed rapamycin can extend the replicative lifespan of human cells. [1]
The description says the guests discuss what happens when mTOR remains active in senescent cells. [1]
The description says the guests moved from basic science to a controlled human study of topical rapamycin. [1]
Rapamycin, mTOR and cell lifespan in the lab
The description says the episode covers early experiments showing that rapamycin can extend the replicative lifespan of human cells. It also says the guests discuss what happens when mTOR remains active in senescent cells. Chris Sell is described as having spent decades studying cellular senescence, IGF signaling, mTOR and rapamycin. These are described as laboratory findings; the description does not report results in people from these experiments. [1]
Topical rapamycin study in aging human skin
The description says the guests moved from basic science to a controlled human study of topical rapamycin. The question posed is whether targeting mTOR with topical rapamycin could improve the function and appearance of aging human skin. Christina Chung is described as a dermatologist whose work with transplant patients gave her a different perspective on rapamycin and its effects on skin biology. The description does not give the study's size, duration, comparison group or results. [1]
Hype in aesthetics and the FDA approval route
The description says the episode contrasts scientifically rigorous skin rejuvenation with the large amount of hype in the aesthetics industry. It also says Hayflick is pursuing the more difficult path of FDA approval, and that the conversation addresses how interventions affecting fundamental aging mechanisms can be translated into therapies that can be tested, approved and used in people. The host discloses serving on the company's Scientific Advisory Board. [1]
Context & limits
This is only the video description; the video and transcript were not reviewed. The description gives no study size, duration, comparison group or results, and no human outcomes are reported. The host discloses a role on the company's Scientific Advisory Board.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
extend the replicative lifespan of human cells
when mTOR remains active in senescent cells
a controlled human study of topical rapamycin
About this video
Creator description · original textText language: American English
Matt Kaeberlein · 60 min · Source published: 2026-10-12
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.